Bioventus Inc
BVS7.460USD
+0.080+1.08%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
499.62MMarket Cap
47.61P/E TTM
More Details of Bioventus Inc Company
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Bioventus Inc Info
Ticker SymbolBVS
Company nameBioventus Inc
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)
Number of employees930
Security typeOrdinary Share
Fiscal year-endFeb 11
Address4721 Emperor Boulevard, Suite 100
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27703
Phone19194746700
Websitehttps://www.bioventus.com/
Ticker SymbolBVS
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)
Company Executives of Bioventus Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
134.37K
+7.98%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
105.96K
+33.34%
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
100.12K
--
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
85.24K
+45.10%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
79.62K
+74.79%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
76.44K
+53.05%
Ms. Michelle Mcmurry-Heath, M.D., Ph.D.
Ms. Michelle Mcmurry-Heath, M.D., Ph.D.
Independent Director
Independent Director
57.00K
-23.70%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
11.70K
--
Mr. Mark Singleton
Mr. Mark Singleton
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Ms. Katrina Church, J.D.
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
134.37K
+7.98%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
105.96K
+33.34%
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
100.12K
--
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
85.24K
+45.10%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
79.62K
+74.79%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
76.44K
+53.05%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Pain Treatments and Joint Preservation
73.31M
49.65%
Surgical solutions
52.72M
35.70%
Restorative Therapies
21.64M
14.65%
By RegionUSD
Name
Revenue
Proportion
United States
128.78M
87.21%
International
18.89M
12.79%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Pain Treatments and Joint Preservation
73.31M
49.65%
Surgical solutions
52.72M
35.70%
Restorative Therapies
21.64M
14.65%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EW Healthcare Partners
19.44%
Juniper Investment Company, LLC
10.36%
Smith & Nephew Group plc
9.30%
Nantahala Capital Management, LLC
8.68%
The Vanguard Group, Inc.
4.30%
Other
47.92%
Shareholders
Shareholders
Proportion
EW Healthcare Partners
19.44%
Juniper Investment Company, LLC
10.36%
Smith & Nephew Group plc
9.30%
Nantahala Capital Management, LLC
8.68%
The Vanguard Group, Inc.
4.30%
Other
47.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
22.94%
Venture Capital
19.55%
Investment Advisor
15.40%
Hedge Fund
14.00%
Corporation
9.30%
Individual Investor
2.50%
Research Firm
1.72%
Insurance Company
0.47%
Bank and Trust
0.20%
Other
13.93%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
319
49.87M
91.76%
-1.55K
2025Q3
324
49.87M
92.42%
+451.64K
2025Q2
315
49.43M
88.24%
+1.39M
2025Q1
300
47.59M
85.68%
-9.15M
2024Q4
302
46.29M
87.45%
+580.76K
2024Q3
303
45.64M
84.02%
-1.26M
2024Q2
271
47.35M
78.83%
+4.38M
2024Q1
269
42.96M
79.86%
-7.88M
2023Q4
267
41.98M
81.20%
+236.50K
2023Q3
256
41.69M
80.71%
+844.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EW Healthcare Partners
13.02M
19.47%
--
--
Jun 30, 2025
Juniper Investment Company, LLC
6.94M
10.37%
--
--
Jun 30, 2025
Smith & Nephew Group plc
6.23M
9.31%
--
--
Apr 07, 2025
Nantahala Capital Management, LLC
5.28M
7.89%
+1.16M
+28.00%
Jun 30, 2025
The Vanguard Group, Inc.
2.77M
4.14%
+223.28K
+8.77%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.82M
4.21%
+259.59K
+10.15%
Jun 30, 2025
Royce Investment Partners
1.09M
1.63%
+199.86K
+22.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.05M
1.58%
+122.14K
+13.09%
Jun 30, 2025
American Century Investment Management, Inc.
1.12M
1.68%
+79.83K
+7.64%
Jun 30, 2025
Kent Lake PR LLC
350.04K
0.52%
+350.04K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Vanguard US Multifactor ETF
0.1%
VictoryShares Small Cap Free Cash Flow ETF
0.1%
Harbor Human Capital Factor US Small Cap ETF
0.09%
Fidelity Enhanced Small Cap ETF
0.09%
iShares Micro-Cap ETF
0.06%
Principal U.S. Small-Cap ETF
0.05%
Vanguard US Value Factor ETF
0.04%
Humankind US Stock ETF
0.03%
WisdomTree US SmallCap Fund
0.03%
Avantis US Small Cap Value ETF
0.03%
View more
Vanguard US Multifactor ETF
Proportion0.1%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.1%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.09%
Fidelity Enhanced Small Cap ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.06%
Principal U.S. Small-Cap ETF
Proportion0.05%
Vanguard US Value Factor ETF
Proportion0.04%
Humankind US Stock ETF
Proportion0.03%
WisdomTree US SmallCap Fund
Proportion0.03%
Avantis US Small Cap Value ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bioventus Inc?
The top five shareholders of Bioventus Inc are:
EW Healthcare Partners holds 13.02M shares, accounting for 19.47% of the total shares.
Juniper Investment Company, LLC holds 6.94M shares, accounting for 10.37% of the total shares.
Smith & Nephew Group plc holds 6.23M shares, accounting for 9.31% of the total shares.
Nantahala Capital Management, LLC holds 5.28M shares, accounting for 7.89% of the total shares.
The Vanguard Group, Inc. holds 2.77M shares, accounting for 4.14% of the total shares.
EW Healthcare Partners holds 13.02M shares, accounting for 19.47% of the total shares.
Juniper Investment Company, LLC holds 6.94M shares, accounting for 10.37% of the total shares.
Smith & Nephew Group plc holds 6.23M shares, accounting for 9.31% of the total shares.
Nantahala Capital Management, LLC holds 5.28M shares, accounting for 7.89% of the total shares.
The Vanguard Group, Inc. holds 2.77M shares, accounting for 4.14% of the total shares.
What are the top three shareholder types of Bioventus Inc?
The top three shareholder types of Bioventus Inc are:
EW Healthcare Partners
Juniper Investment Company, LLC
Smith & Nephew Group plc
EW Healthcare Partners
Juniper Investment Company, LLC
Smith & Nephew Group plc
How many institutions hold shares of Bioventus Inc (BVS)?
As of 2025Q4, 319 institutions hold shares of Bioventus Inc, with a combined market value of approximately 49.87M, accounting for 91.76% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.66%.
What is the biggest source of revenue for Bioventus Inc?
In FY2025Q2, the Pain Treatments and Joint Preservation business generated the highest revenue for Bioventus Inc, amounting to 73.31M and accounting for 49.65% of total revenue.
